A twofold change in the cisplatin (DDP) sensitivity of 2008 human ovarian carcinoma cells is sufficient to reduce tumor response in vivo. The DDP sensitivity of these cells can be enhanced by activation of the epidermal growth factor and protein kinase C signal transduction pathways. We report here that two endogenous growth factors, bombesin and tumor necrosis factor alpha (TNFa), enhanced DDP sensitivity by factors of 1.7±0.1 (SD)-fold and 1.8±0.1 (SD)-fold, respectively. Both agents also produced sensitization in an 1 1-fold DDP-resistant 2008 subline. Neither bombesin nor TNFa changed the accumulation of DDP, glutathione content, or glutathione-Stransferase activity in 2008 cells. However, a 2-h exposure to both bombesin and TNFa was sufficient to increase 2008 cloning efficiency by up to 2.6±0.1 (SD)-fold and 2.2±0.1 (SD)-fold, and it increased average colony size by 1.35±0.1 (SD)-fold and 1.55±0.1 (SD)-fold, respectively. Bombesin increased intracellular free calcium, and this was blocked by the bombesin receptor-specific antagonist SC196, demonstrating that 2008 cells have functional bombesin receptors. These results indicate that bombesin and TNFa can enhance sensitivity to DDP in both DDP sensitive and resistant variants of a human ovarian carcinoma and that both agents serve as growth factors for this tumor.
Introduction
Ligand binding to a variety ofreceptors triggers the rapid generation of inositol triphosphate and diacylglycerol leading to the activation of protein kinase C (PKC)1 ( 1 ). Bombesin, a tetra-([3H]-ethylenediamine)-platinum(II); EGF, epidermal growth factor; GST, glutathione-S-transferase; mCB, monochlorobimane; PKC, protein kinase C; TNFa, tumor necrosis factor-alpha; TPA, 12-O-tetradecanoylphorbol-I 3-acetate. decapeptide originally isolated from frog skin (2) , has been shown to act as a mitogen for Swiss 3T3 fibroblasts (3) and human small cell lung carcinomas (4) . This peptide also has potent pharmacological effects on pancreatic cells (5) and elicits the release of other peptide hormones such as insulin. Since the administration ofthis hormone stimulates the release of other peptides, it is difficult to obtain evidence for a direct biological activity ofbombesin. In Swiss 3T3 cells, high affinity receptors specific for this peptide have been demonstrated (6) , and bombesin is able to directly activate PKC (7) . There is also indirect evidence that bombesin can activate PKC in human tumor cells based on its ability to generate inositol triphosphates and increase intracellular free calcium [(Ca2+)i] (5, 8) .
Tumor necrosis factor-a (TNFa), secreted by macrophages (9) , is a cytokine with a wide range ofregulatory actions on immune responses, inflammation, cell growth, and differentiation (10) . TNFa has been reported to enhance the cytotoxicity of cis-diamminedichloro-platinum(II) (DDP) in vitro to a human stomach adenocarcinoma ( 1) and a human ovarian carcinoma cell line ( 12) . In contrast, TNFa does not demonstrate an actual synergistic effect when combined with DDP in a human bladder transitional cell carcinoma in vivo ( 13) . Furthermore, when TNFa was administered for the treatment of intraperitoneal ovarian cancer xenografts, although it prolonged survival in tumor-bearing mice (10) , it also promoted the establishment of multiple subperitoneal tumors. O-tetradecanoyl-phorbol-l 3-acetate (TPA), TNFa activates PKC in some cell types and this in turn may result in increased AP-l activity and induction of AP-l-responsive genes ( 14) . This is considered to be a key mechanism mediating at least some of the biological effects of TNFa mentioned above.
We have previously reported that TPA activation of PKC increased DDP sensitivity by a factor of 2.5-fold in human ovarian carcinoma 2008 cells ( 15) . Likewise, epidermal growth factor (EGF), another potent activator of PKC, enhances DDP sensitivity by 3.1-fold in the same cell line ( 16 5 MM ( 19) . The cells were grown on tissue culture dishes in a humidified incubator at 370C in a 5% CO2 atmosphere. They were maintained in medium consisting of RPMI 1640 supplemented with 5% heat inactivated fetal calf serum, 2 mM glutamine, 100 U/ml penicillin, and 100 Ag/ml streptomycin (Irvine Scientific, Santa Ana, CA).
Bombesin and TNFa treatment and colony assays. Colony-forming assays were used to assess the mitogenic and sensitization effects of each factor (20 Tris-Cl, pH 8.0; 25 mM EDTA; 0.5% SDS; 0.1 mg/ml proteinase K, and digested at 50'C for 18 h with shaking. This was followed by extraction with phenol/chloroform, and the DNA was redissolved in 10 mM Tris-Cl pH 8.0, 1 mM EDTA containing 0.1 mg/ml RNase A and digested at 370C for 3 h. After another extraction with phenol/chloroform, the DNA was precipitated with 70% ethanol and stored at -70'C. The platinated DNA was digested to deoxyribonucleosides and specific DNA-bound adducts were separated by HPLC (22) . The peak height of deoxycytosine measured at 254 nm during elution was converted to nanomoles by comparison with a standard curve. The level of DNA platination was then expressed as dpm associated with the intrastrand guanine-guanine adduct/nmol deoxycytosine.
Cell cycle phase distribution. 1 x 106 log phase cells were exposed to bombesin or TNFa for 2 h while growing as a monolayer, after which the medium was replaced. Cells were harvested by trypsinization at 24, 48, and 72 h after exposure, fixed with ice-cold 70% ethanol, and then resuspended at 106 cells/ml in PBS containing 50 MM propidium iodide and 1,000 U/ml RNase A and incubated for 30 min at 370 before being analyzed on a flow cytometer(CytoFluorograph; Ortho Diagnostics Systems, Inc.). The fraction of cells in each phase was determined using Multicycle Cell Cycle Software (Phoenix Flow Systems, San Diego, CA). in NaCl Ringer's solution maintained at 37°C and pH 7.4 by aeration using a 95% 02 5% CO2 gas mixture. Loaded cells were then placed onto a glass coverslip that had previously been coated with 5 mg/ml poly-L-lysine (Sigma Chemical Co.). The coverslip was then briefly rinsed in NaCl, removing any remaining extracellular dye but leaving a number of cells attached to the poly-L-lysine coating, and then was attached with high vacuum grease to a donut-shaped glass tube, creating a chamber in which the cell-coated coverslip served as the floor. The glass-tubing wall of the chamber circulated heated water, and thus the NaCl added to the chamber to bathe the cells, again aerated to pH 7.4, was maintained at 37°C. This chamber was placed on an inverted microscope (Nikon Diaphot; Nikon Corp., Melville, NY), which was fiberoptically connected to a spectrofluorometer (SPEX AR-CM DM3000; SPEX Industries Inc., Edison, NJ). For each experiment, a small group (5-10) of loaded cells was selected and alternately excited at 340 nm and 380 nm while fluorescent emissions were measured at 505 nm. Initially, emissions were measured while the cells were being bathed in NaCl. After 60-120 s, 300 nM bombesin was added to the bath and scanning continued. Approximately 2 min later, 25 MM ofthe calcium ionophore ionomycin (Sigma Chemical Co.) was added to the solution, followed in -60 s by the addition of 60-120 mM of the calcium-chelating agent, EGTA (Sigma Chemical Co.). These last two additions were necessary for calibration of the FURA dye emissions to calculate (Ca2+)i levels using the Grynkiewicz Equation (23). Emission intensities from 2008 cells that were not loaded with the fluorescent probe were similarly recorded, and these measured "autofluorescent" emissions were subtracted from measured intensities emitted by the loaded cells before calculating (Ca2+)i concentrations.
In a second set of experiments, identically loaded 2008 cells were exposed for 15 min to 30 MM SC196, Ac-Met-Tyr-Pro-Arg-Gly-AsnHis-Trp-Ala-Val-Gly-His-LeufLeu-NH2 (a generous gift of Drs. John Steward and Lajos Gere, UCHSC, Denver, CO), a highly specific bombesin-receptor antagonist (24) , before excitation. Initially, cells were excited while being bathed in NaCl plus 30 MM SC 196. Bombesin 300 nM was added to the physiologic solution after 2 min. The ratio of 340:380 nm emission intensities was calculated to determine whether changes in (Ca2+)i concentrations occurred in response to the addition of bombesin.
Results
Effect ofbombesin and TNFa on DDP sensitivity. Fig. I (left) shows that when 2008 cells were exposed concurrently for 2 h to 300 nM bombesin and DDP, and then both agents were removed from the cultures during the period of colony formation, bombesin increased DDP sensitivity. The IC50 in the absence ofbombesin was 4.50±1.0 ,uM (SD), whereas in the presence of bombesin it was 2.67±0.21 jM (SD). Thus, bombesin produced a 1.7-fold increase in sensitivity (n = 3; P < 0.01). Likewise, the Fig. 1 (right) shows that when 2008 cells were exposed concurrently for 2 h to 2.4 nM TNFa and DDP, TNFa increased DDP sensitivity. The IC50 in the presence of TNFa was 2.57±0.29 ,uM (SD). Thus, TNFa produced a 1.8-fold increase in sensitivity (n = 3; P < 0.01). Both bombesin and TNFa at concentrations even up to 10 and 120 ,uM did not cause any toxicity by themselves; thus, the interaction between bombesin and TNFa and DDP was truly synergistic as defined by median effect analysis (25) .
Enhancement of sensitivity in DDP-resistant cells. The 2008/C13*5 cell line is 11-fold resistant to DDP. Fig. 2 (left) shows that when these cells were exposed for 2 h concurrently to bombesin and DDP, the IC50 was reduced from 39.0 to 21.5 ,uM. The 1.6±0.3 (SD)-fold sensitization, quantitated by change in the slope of linear portion of these dose-response curves, was nearly identical to the 1.7-fold sensitization observed in the DDP-sensitive 2008 cells (n = 3; P < 0.01 ). Similarly, Fig. 2 (right) shows that when cells were exposed for 2 h concurrently to TNFa and DDP, the IC50 was reduced to 22.5 ,M. The 1.6±0.9 (SD)-fold sensitization, quantitated by change in the slope of these curves, was likewise nearly identical to the 1.8-fold sensitization observed in the DDP-sensitive 2008 cells (n = 3; P < 0.01). Dose-dependent effect ofbombesin and TNFa on clonogenicity of2008 cells. Fig. 3 Effect ofbombesin and TNFa on colony-size distribution. Table I shows that, like the effect on cloning efficiency, the effect of bombesin and TNFa on mean colony size was also concentration dependent. Despite the small size ofthe colonies in these experiments (cells were incubated for 10 d after drug treatment) compared with the data presented above, bombesin significantly increased the colony size at each dose level (n = 20; P < 0.01), and the maximum colony size was observed at a bombesin concentration of 400 nM. Similarly, TNFa significantly increased the colony size in each dose level (n = 20; P < 0.01), and the maximum colony size was observed at a TNFa concentration of 4.0 nM. The maximum increase in mean colony size with bombesin was 1.36±0.07 (SD)-fold, whereas it was somewhat larger at 2.04±0.10 (SD)-fold with TNFa (n = 20; P < 0.01 ).
Effect ofbombesin and TNFa on growth rate of2008 cells. An increase in apparent cloning efficiency and mean colony size is most readily explained by an increase in cell-doubling A further demonstration of the mitogenic effect of bombesin and TNFa is shown in Fig. 5 . Cells were treated with a single 2-h exposure to 300 nM bombesin or 2.4 nM TNFa, washed, and the cell cycle phase distribution determined by flow cytometry at 24-h intervals for 3 d. Both agents produced an increase in the fraction of cells in S phase at the expense of GI phase by 24 h (P < 0.05 for both). After exposure to TNFa this cell-cycle phase perturbation returned to normal by 48 h; the response was more prolonged with bombesin, requiring 72 h to return to baseline. Control cells, which were plated at the same density as bombesin-and TNFa-treated cells, showed no perturbation of the cell cycle phase distribution during the 72-h observation period. This indicates that during the experiment the cells remained in log phase growth. These Fig. 6 , which also shows that the bombesin-specific antagonist SC196 completely blocked the ability of 300 nM to elevate (Ca2+). This blockade was observed in 100% of the 60 cells examined.
Effect ofcell density on DDP sensitivity. the starting parent culture has no effect on final DDP cell survival.
Discussion
The finding that bombesin induces activation of PKC (7) and the wide distribution of endogenous mammalian analogs of bombesin (26) suggest that this peptide may play an important role in controlling the phenotype of both normal and malignant cells. Such a role has already been established for TNFa, which is also capable ofactivating PKC in some cell types (14) . The first major finding resulting from the studies reported here was that the signal transduction pathways activated by both bombesin and TNFa can modulate the sensitivity of the human ovarian carcinoma cell line 2008 to DDP, the most clinically important drug for the treatment ofthis malignancy. The effect was produced by exposure to growth factor forjust 2 h, indicating that enhancement of sensitivity was the result of the triggering of a cascade of events initiated by ligand binding rather than a mechanism that required the continuous presence of exogenous ligand. Other investigators have also found that TNFa will modulate DDP sensitivity in a human ovarian carcinoma (12) and a gastric adenocarcinoma (11) 29) . The mechanism by which signal transduction activators modulate DDP sensitivity appears to vary. In the case of activation of the protein kinase A pathway, the major effect is an increase in DDP uptake (27) , whereas activation of the EGF receptor or PKC does not alter uptake (15, 16) . Bombesin and TNFa were selected for study because they are possible endogenous activators of PKC (9, 26) . Like TPA they failed to enhance DDP uptake, produced no change in GSH content or apparent GST activity, and did not alter the number of intrastrand cross-links formed. It is unlikely that enhancement of DDP sensitivity is mediated by a decrease in metallothioneins since these are relatively stable proteins with cellular half-lives of many hours ( 15) (16) . We speculate that the effects of bombesin and TNFa on the growth of 2008 cells may be indirect, and that brief exposure to either may be initiating the production of an autocrine growth factor that either produces and maintains the alteration in cytokinetics or potentiates such effects of factors already present in the culture medium. It is important to emphasize that the ability of bombesin and TNFa to enhance DDP sensitivity may not be linked to their mitogenic effects; these may be entirely independent effects of receptor activation.
The concentration of bombesin causing mitogenesis in 2008 cells was substantially higher (maximum effect 4,000 nM) than that required for mitogenesis in Swiss 3T3 (33) or human small cell lung carcinoma lines (34) cells, raising the question of whether bombesin was working via another receptor. However, the studies with Swiss 3T3 and nonsmall cell lung cancer cells lines used continuous exposure to bombesin or gastrin-releasing peptide, whereas the dose-response curve depicted in Fig. 3 was obtained using only a 2-h exposure.
Moreover, the ability of the bombesin receptor-specific inhibitor SC 196 to block the bombesin-induced increase in (Ca2+) established that the 2008 cells do contain bona fide bombesin receptors but not that this receptor type is responsible for the mitogenic or sensitizing response. These cells may also contain neuromedian B receptors, and it is possible that both receptor types may contribute to the mitogenic or sensitizing responses or that bombesin is producing these responses indirectly via another growth factor that is less effective on 2008 than the Interest in TNFa as a potential regulator of DDP sensitivity and/or tumor growth in human ovarian carcinoma is heightened by reports that a significant fraction of these tumors appear to produce TNF (35) and that TNF treatment of several human ovarian carcinoma xenografts increases their local invasiveness ( 10) . TNFa is currently being tested in the United States as a treatment for ovarian carcinoma. Both our results and those of other investigators ( 10, 35, 36) suggest the need for caution and careful assessment of whether TNFa might be detrimental to such patients.
